Resurgence of pertussis at the age of vaccination: clinical, epidemiological, and molecular aspects

• Main Authors: Rosângela S.L.A. Torres (Author), Talita Z. Santos (Author), Robson A.A. Torres (Author), Valéria V.G. Pereira (Author), Lucas A.F. Fávero (Author), Otavio R.M. Filho (Author), Margareth L. Penkal (Author), Leni S. Araujo (Author)
• Format: Book
• Published: Brazilian Society of Pediatrics, 2015-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2255-5536; 10.1016/j.jpedp.2015.04.006
• Keywords: Whooping cough; Clones; Bordetella pertussis; Rep‐PCR; Vaccine; Incidence; Pediatrics; RJ1-570
• Source: Jornal de Pediatria (Versão em Português), Vol 91, Iss 4, Pp 333-338 (2015)

Objective: Report the incidence, epidemiology, clinical features, death, and vaccination status of patients with whooping cough and perform genotypic characterization of isolates of B. pertussis identified in the state of Paraná, during January 2007 to December 2013. Methods: Cross‐sectional study including 1,209 patients with pertussis. Data were obtained through the Notifiable Diseases Information System (Sistema de Informação de Agravos de Notificação - SINAN) and molecular epidemiology was performed by repetitive sequence‐based polymerase chain reaction (rep‐PCR; DiversiLab®, bioMerieux, France). Results: The incidence of pertussis in the state of Paraná increased sharply from 0.15‐0.76 per 100,000 habitants between 2007‐2010 to 1.7‐4.28 per 100,000 between 2011‐2013. Patients with less than 1 year of age were more stricken (67.5%). Fifty‐nine children (5%) developed pertussis even after receiving three doses and two diphtheria‐tetanus‐pertussis (DTP) boosters vaccine. The most common complications were pneumonia (14.5%), otitis (0.9%), and encephalopathy (0.7%). Isolates of B. pertussis were grouped into two groups (G1 and G2) and eight distinct patterns (G1: P1‐P5 and G2: P6‐P8). Conclusion: The resurgence of pertussis should stimulate new research to develop vaccines with greater capacity of protection against current clones and also encourage implementation of new strategies for vaccination in order to reduce the risk of disease in infants.